Article snapshot taken from Wikipedia with creative commons attribution-sharealike license.
Give it a read and then ask your questions in the chat.
We can research this topic together.
Vamicamide, also known as FK-176 or Urocut, is a muscarinic acetylcholine receptor (mAChR) antagonist that was developed by Fujisawa (now part of Astellas Pharma) for the treatment of urinary incontinence and overactive bladder. This small molecule drug acts by blocking muscarinic receptors, which play a role in bladder function. Despite showing promise in preclinical studies for increasing bladder capacity without affecting other urinary parameters, vamicamide has never been approved for medical use. The drug's development was ultimately discontinued, with its highest research and development status reaching the New Drug Application (NDA) phase in Japan.
Yamamoto T, Koibuchi Y, Miura S, Sawada T, Ozaki R, Esumi K, Ohtsuka M (December 1995). "Effects of vamicamide on urinary bladder functions in conscious dog and rat models of urinary frequency". The Journal of Urology. 154 (6): 2174–8. PMID7500484.